CorMedix (CRMD)

• Market cap: $635M
• 1 day: 0.87%
• 5 days: -1.13%
• 1 month: -0.10%
• 3 months: 25.99%
• 6 months: 48.30%
• Year to date: 27.37%
• 1 year: 150.48%
• 5 years: 247.84%
• 10 years: -74.12%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets.

Employees: 82

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

264% more first-time investments, than exits

New positions opened: 40 | Existing positions closed: 11

100% more repeat investments, than reductions

Existing positions increased: 48 | Existing positions reduced: 24

66% more call options, than puts

Call options by funds: $6.64M | Put options by funds: $4M

26% more funds holding

Funds holding: 102 [Q3] → 129 (+27) [Q4]

19% more capital invested

Capital invested by funds: $156M [Q3] → $186M (+$30M) [Q4]

3.24% more ownership

Funds ownership: 34.63% [Q3] → 37.86% (+3.24%) [Q4]

50% less funds holding in top 10

Funds holding in top 10: 2 [Q3] → 1 (-1) [Q4]

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $12 15% upside
• Avg. target: $15 43% upside
• High target: $18 72% upside

3 analyst ratings

• positive: 3 100%
• neutral: 0 0%
• negative: 0 0%

Leerink Partners Roanna Ruiz 33% 1-year accuracy 3 / 9 met price target	72% upside $18	Outperform Initiated	7 Mar 2025
D. Boral Capital Jason Kolbert 28% 1-year accuracy 77 / 280 met price target	43% upside $15	Buy Maintained	5 Mar 2025
RBC Capital Gregory Renza 34% 1-year accuracy 25 / 73 met price target	15% upside $12	Outperform Maintained	19 Dec 2024